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Abstract
The effects of cannabis use on the brain, mind, and body have been studied for
decades. The developing brain, particularly the adolescent and young adult brain, undergoes
critical development that makes it especially susceptible to the effects of cannabis use. Among
the adverse effects of cannabis use in adolescence and young adulthood, psychosis, and
psychotic disorders (e.g., schizophrenia) have been examined. The association of cannabis use
with schizophrenia was first elucidated in a Swedish study of army conscripts. Specifically,
conscripts reported their cannabis use exposure and were followed longitudinally to assess the
emergence of schizophrenia. The authors found that those who reported persistent cannabis
use during adolescence had higher rates of schizophrenia diagnoses.
Notwithstanding this correlation, a causal relationship has not yet been established
between adolescent cannabis use and schizophrenia. Some believe that in the premorbid phase
of schizophrenia, one may self-medicate with cannabis, accounting for the correlational
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relationship. However, this evidence is not supported by the literature. Prolonged, frequent use
of exogenous cannabinoids such as phytocannabinoids and synthetic cannabinoids perturb the
endocannabinoid system, particularly during the critical period of adolescence. Many
researchers believe this perturbation contributes to psychosis and the pathogenesis of
schizophrenia.
Keywords: cannabis, schizophrenia, psychosis, adolescence

Associations Between Cannabis, Psychosis, and Schizophrenia in Adolescents
The relationship between cannabis use, psychosis, and schizophrenia has been studied
for decades. As cannabis is the most utilized mood-altering drug in the United States and the
world (Abush et al., 2018), many researchers are interested in its effects on mental health.
However, despite the extensive literature on cannabis, psychosis, and schizophrenia, the causal
nature of these interrelationships remains unclear. Indeed, this relationship involves other
factors that may confound it. As stated previously, cannabis is the most widely used drug in
many developed and underdeveloped societies. However, its public health and psychiatric
effects are not widely understood and are the subject of intense polemics. Cannabis is derived
from the female plant of cannabis sativa. It contains over 400 cannabinoids, one of which is the
primary psychoactive component delta-9 tetrahydrocannabinol (THC). From a pharmacological
perspective, a cannabinoid is a category of chemical compounds such as phytocannabinoids,
synthetic cannabinoids, and endogenous cannabinoids that bind to CB1 and CB2 receptors
(Oleson & Cheer, 2012).
Cannabis also includes cannabidiol (CBD), which does not have psychoactive properties
and has been purported to counterbalance the effects of THC. However, THC produces several
pharmacological effects in humans and animals (Adams & Martin, 1996). Over the last few
decades, progress has been made in categorizing cannabinoids and the cannabinoid receptors
in the endocannabinoid system, which communicate with other messenger systems at the
cellular level. Although THC will be discussed most extensively throughout this review, the
primary purpose is to examine the association between cannabis, psychosis, and
schizophrenia. Although there appear to be interrelationships, there are critical differences
between schizophrenia and cannabis-induced psychosis (CIP). As these relationships were
analyzed, the following research question was asked: For those who use cannabis in
adolescence, do they experience more instances of cannabis-induced psychosis, and does it
lead to higher occurrences of schizophrenia?
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Methods
Google Scholar and PubMed were the databases utilized to conduct this literature
review. Upon initial search, the terms "cannabis-induced psychosis" AND "schizophrenia" were
used. This search yielded 237,908 results. The results were narrowed to 1,908 by clicking on
"adolescence." PubMed was chosen due to its public interface searchable via MEDLINE and
the National Library of Medicine. It is the most comprehensive database for biomedical
literature. Google Scholar was selected because it shows articles within search parameters and
articles related to topics of interest. These terms yielded articles about schizophrenia and
cannabis-induced psychosis.
Differences Between Schizophrenia and Cannabis – Induced Psychosis
One of the significant differences between schizophrenia and CIP is the duration of
symptoms. Psychosis can be a symptom of many mental illnesses, whereas schizophrenia is a
chronic illness that requires a lifetime of treatment (American Psychiatric Association, 2013). In
schizophrenia, symptoms persist despite drug abstinence. However, symptoms in CIP abate or
are reduced in abstinence. People with schizophrenia may test positive on urine toxicology if
they engage in cannabis consumption. However, a positive toxicology screen in an individual
with CIP indicates a clear timeline of the time of last drug ingestion. This timeline will also
indicate if psychosis is closely related to the cannabis intoxication/withdrawal effects.
One of the features of CIP is the sudden onset of mood lability and paranoid symptoms.
These symptoms usually occur within a week of use. Therefore, criteria for CIP must exclude
the diagnosis of schizophrenia. These symptoms should also be more than anticipated
intoxication and withdrawal symptoms. In terms of the appearance of symptoms, schizophrenia
appears in the absence of cannabis use. With CIP, symptoms only occur during periods of
heavy (2 grams per day or more) use. In addition, CIP has traditionally been concomitant with
fewer negative symptoms than schizophrenia. Nevertheless, in the absence of a clear timeline
of cannabis use, distinguishing schizophrenia from CIP may be problematic. This may lead to
an incorrect intervention. Many of the clinical features of schizophrenia share many overlapping
characteristics with CIP. However, in comparison with schizophrenia, CIP has been recognized
to show more mood symptoms.
One of the most salient features of CIP is insight. In schizophrenia, there is less insight
into their psychotic state. However, there is more awareness of CIP. Insight is the most
discerning characteristic of CIP due to the cognizance of one's clinical condition, greater
disease insight, and the ability to identify symptoms as a manifestation of substance use. The
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existence of much more rapidly declining positive symptoms is also a distinguishing factor of
CIP. Lastly, in schizophrenia, disorganized thought-form such as loose associations and
tangential or circumstantial speech is present. However, with CIP, thought is more sequential
and organized. Although there are prominent differences, both syndromes can affect
adolescents.
Associations Between Cannabis, Psychosis, and Schizophrenia in Adolescents
Prolonged cannabis use has been correlated with schizophrenia (Lubman et al., 2015).
The neurological basis of this association, while not fully understood, points to the use of
cannabis among those who are vulnerable to schizophrenia leading to psychosis and cognitive
impairments, particularly when use begins in adolescence. The endocannabinoid system (ECS)
plays a pivotal role in brain development. Therefore, it is plausible that early and frequent use of
cannabis perturbs the neuromaturational processes occurring in this system during
adolescence, leading to psychosis and schizophrenia. White matter development and synaptic
pruning are two aspects that have been identified as being inversely impacted by cannabis
exposure during the critical period of adolescence (Harley et al., 2010).
According to Zuurman et al. (2009), cannabis disrupts the nervous system in multiple
ways. This disruption may result in perceptual distortions, relaxation, euphoria, increased
sensory perception, anxiety, hunger, and dizziness. Quickfall and Crockford's (2006) study
examined brain function during acute THC intoxication and discovered increased cerebral blood
flow in the limbic, paralimbic, frontal, and cerebellar regions associated with use. This study
found that there are biochemical effects due to the opposing characteristics of THC and CBD.
Indeed, other researchers have found that THC produces anxiety and cognitive and perceptual
disturbances while CBD produces anxiolytic effects (Zuardi et al., 1993; Bergamaschi et al.,
2011) and can have antipsychotic properties (Zuardi et al., 2006). These studies have also
indicated that CBD can thwart the effects of THC (Zuardi et al., 1982). Although the association
between the biochemical effects of the adolescent brain and Cannabis sativa is still under
investigation, many articles in the literature point to this relationship and the etiology of
schizophrenia.
Etiology of Schizophrenia
Schizophrenia is one of the most debilitating diseases in psychiatry. One of the many
reasons for its debilitating symptoms is a misunderstanding among the psychiatric and lay
community regarding its cause and effective treatments. According to the Diagnostic and
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Statistical Manual (DSM 5), schizophrenia may consist of disorganized speech, disorganized
and catatonic behavior, delusions, hallucinations, and negative symptoms (American Psychiatric
Association, 2013). Two or more of these symptoms must be present for one month or more to
diagnose the disorder. The construct of schizophrenia in the DSM 5 has been proven to have
high reliability and validity.
The cause of schizophrenia, despite over a century of studying its pathogenesis,
etiology, pathophysiology, and pharmacological outcomes, is unknown. However, a significant
amount of evidence has suggested that it is associated with excessive stimulation of striatal
dopamine (DA) D2 receptors; deficient stimulation of prefrontal D1 receptors; and alterations in
prefrontal connectivity involving glutamate (GLU) transmission involving N-methyl-D-aspartate
(NMDA) receptors (Laruelle et al., 2003). In addition, postmortem studies have suggested
abnormalities in the expression of GLU-related proteins (Laruelle et al., 2003); however, these
studies have yet to be reproduced. Clinical studies have also suggested that schizophrenia
features low cerebrospinal fluid homovanillic acid, which is a measure that also indicates low DA
activity in the prefrontal cortex (PFC).
Further evidence supporting the role of dopamine in schizophrenia derives from the
efficacy of dopaminergic stabilizers in treating schizophrenia. Dopaminergic stabilizers have
been shown to reestablish social behavior in rat models (Brisch et al., 2014). These studies
have also shown that cognitive deficits associated with cannabis use are associated with DA
decline in the PFC observed in schizophrenia. For example, in a survey of adolescents after 12
hours of abstinence from cannabis, those who used more than once per week had considerably
poorer performance on several measures of cognitive function reflecting attention, spatial
working memory, and learning (Harvey et al., 2007). These analyses suggest that aspects of
adolescent cognitive function are autonomously related to the regularity of cannabis use beyond
acute intoxication. These deficits also include executive functioning, language, processing
speed, inhibition of attention, and sensory processing. The PFC is particularly concomitant with
working memory. Auditory processing is also an impairment in those with schizophrenia.
According to the literature, adolescent brain development is particularly vulnerable to
exogenous insults.
Adolescent Brain Development
Adolescence is an important stage in cognitive and behavioral development that features
significant neuromaturation. This maturation includes substantial changes in all neuronal
domains that affect behavior, cognition, and affect (Steinberg, 2007). Areas of the brain that
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develop during adolescence contribute to the ability to perform complex psychological tasks.
During this critical stage of development, the transformation of brain regions influences
cognition, sensorimotor systems, and motivation. This period involves synaptic pruning of the
cortical synapses, which leads to a diminution in cortical gray matter and increased myelination
(Giedd et al., 1999; Paus, 2005). The volume of cortical grey matter follows an inverted U-shape
during this period, meaning that most of the region's volume that develops earliest is in areas of
the brain responsible for cognitive functioning. This development occurs during adolescence
and into early adulthood (Giedd et al., 2009). Many researchers assert that disjunctions among
these developing regions render adolescence a critical period that involves increased
susceptibility to mental health disorders such as schizophrenia (Spear, 2000; Steinberg, 2005).
It is also a period of an increased likelihood of disjunctions in the endocannabinoid system for
adolescents and young adults if THC is used.
The endocannabinoid system plays a critical role in neurodevelopment and
neuromaturation. The ECS is comprised of two G-protein-coupled cannabinoid receptors (CB1
and CB2), endocannabinoid ligands, 2-arachidonoyl ethanolamide [2-AG], and the enzymes
involved in amalgamation and degradation (De Petrocellis & Di Marzo, 2009). The CB1
receptor is expressed more often than other G-protein coupled receptors in the brain. This
arbitrates the CNS effects of cannabis; however, the CB2 receptor plays a role in numerous
other physiological systems, particularly in the immune system (Svíženská et al., 2008).
Furthermore, CB1 receptors are located presynaptically, where initiation by endocannabinoids
can constrain conduction in GABAergic and glutaminergic synapses (Freund et al., 2003). Thus,
the ECS is critical in maintaining the balance between inhibitory and excitatory neuronal action.
Also, CB1 inhibition of glutaminergic neurotransmission and regulation of glutamate-induced
excitotoxicity may be the principal mechanism by which cannabinoids exert neuroprotective
influence (Marsicano et al., 2003).
Cannabinoid receptors and endogenous cannabinoids develop early in the brain. This
development includes the production and distinction of progenitor cells, neuronal migration,
axonal pathfinding, and glial cell data (Fride, 2008; Harkany et al., 2008; Díaz-Alonso et al.,
2012). Furthermore, there is growing evidence that the ECS develops during adolescence
(Galve-Roperh et al., 2007; Malone et al., 2010; Galve-Roperh, 2012). Although the role of the
ECS in adolescent neuromaturation has yet to be fully discovered, recent studies show
increased CB1 density during adolescence (Bossong & Niesink, 2010).
Exogenous cannabinoids affect the functioning of the ECS, and researchers purport that
cannabis use during adolescence may represent a disruption of this critical period of
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development (Bossong & Niesink, 2010). Specifically, it may lead to enduring impacts that
increase the likelihood of psychopathology (Bossong & Niesink, 2010; Downer & Campbell,
2010; Malone et al., 2010; Caballero & Tseng, 2012). Most importantly, cannabinoid-related
disruptions in the ECS are positively correlated with schizophrenia (Galve-Roperh et al., 2009;
Parolaro et al., 2010; Ferretjans et al., 2012). The endocannabinoid system regulates the
generation and specification of neural cells during the early postnatal stages of brain
development. In addition, it regulates neural cell maintenance and neuroprotection in the mature
brain (Galve-Roperh et al., 2009).
In the developing adolescent brain, CB1 receptors facilitate neuronal migration and
axonal pathfinding and the production of glial cells, including astrocytes and oligodendrocytes.
There are two plausible mechanisms by which prolonged cannabis exposure during
adolescence might disturb the processes of the endocannabinoid system and modify brain
development: (1) by interfering with processes of synaptic pruning (red pathway); and (2) by
altering the development of white matter (blue pathway).
In those with schizophrenia, deviations in CB1 binding have been found in frontal
regions, including prefrontal and anterior cingulate cortex as well as in the ventral striatum
(Zavitsanou et al., 2004; Newell et al., 2006; Eggan et al., 2010; Wong et al., 2010; Ceccarini et
al., 2013). Some researchers have suggested that augmented receptor binding may intensify
psychotic symptoms in schizophrenia (Wong et al., 2010; Ceccarini et al., 2013). Researchers
have also shown that those with schizophrenia have genetic differences in the components of
the ECS and variations in endocannabinoid levels in the cerebrospinal fluid (CSF) and blood
(Ferretjans et al., 2012). Nonetheless, anomalous activity in the ECS may explain problems in
recollection and academic retention associated with adolescent cannabis use, particularly THC
(Sullivan, 2000; Marsicano & Lafenêtre, 2009).
The ECS consists of endogenous cannabinoids, enzymes, and cannabinoid receptors
(Mackie, 2008). Although researchers initially maintained that the enzymes within this system
degrade endocannabinoids because they activate the same receptors as the exogenous
cannabinoid THC (Guindon & Hohmann, 2009), this early view was shown to be inaccurate
(Watson et al., 2008). The ECS is found in the brain and other parts of the body. ECS has a
pivotal function in many aspects of neurological development, including neural specification,
neurogenesis, neural maturing, neuronal relocation, axonal augmentation, glia development,
and arranging inhibitory GABAergic interneurons and excitatory glutamatergic neurons (De
Petrocellis & Di Marzo, 2009). Thus, when this system becomes distressed, it is susceptible to
many illnesses, including schizophrenia (Svíženská et al., 2008).
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When the ECS becomes distressed by superfluous stimulation in a rapidly changing
brain, such as adolescence and young adult cannabis use, it may have significant
consequences for one's psychological functioning. This distress would be particularly
problematic for a developing brain with a previous altered neurodevelopmental process—that is,
"the diathesis" for schizophrenia or other psychotic illness. Thus, by disrupting the ECS and
disturbing the neurodevelopmental processes, exposure to exogenous cannabinoids during the
critical period may confer increased risk for the development of psychosis and schizophrenia. If
a diathesis is present, this critical period may lead to the emergence of schizophrenia.
Age of Onset of Cannabis Use and the Emergence of Schizophrenia
Multiple studies suggest that adolescence is a critical period of increased vulnerability to
the deleterious effects of frequent cannabis use (Gorey et al., 2019). The earlier the onset, the
more severe the impairment of cognitive domains such as learning, decision-making, memory,
and attention (Fontes et al., 2011; Gruber et al., 2012). It is also essential to consider that
studies examining the association of age of onset of cannabis use and schizophrenia may have
numerous confounding factors (Lisdahl et al., 2013). For example, a longitudinal study of the
association of adolescent cannabis use, academic performance, and mental health among 1037
participants followed from childhood to adulthood. Participants were assessed at various
periods of development, both before the age of onset, between ages 7-13, and at age 38.
Researchers discovered that those between 7 and 13 years of age who self-reported frequent
cannabis exposure or those who received a diagnosis of a cannabis-use disorder before age 18
displayed more neuropsychological deficits than those with a cannabis-use disorder or regular
use limited to adulthood (Meier et al., 2012).
Furthermore, adolescents who use cannabis more than once daily may have
irregularities that persist several years after abstinence, and results are reproducible in adult
samples (Pope et al., 2003). Pope et al. (2003), elucidated the probability of premorbid
aberrations that account for the successive decay in neuromasturational progression. The
continuous abstinence from THC was not enough to recover cognitive abilities when heavy
cannabis use is present in adolescence (Pope et al., 2003). Nevertheless, many have argued
that the correlation between early-onset cannabis use, and cognitive deficits reported by Meier
et al., (2012) may have been confounded by other factors such as socioeconomic status
(Rogeberg, 2013) and personality (Daly, 2013). This possible confounding calls into question
the causal nature of the cannabis-neurological relationship.
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Others have argued that cannabis exposure is linked to schizophrenia in that it may
commence during the premorbid phase of schizophrenia (D'Souza et al., 2005) and represent a
form of self-medication while "feeling off" during this premorbid phase. According to D'Souza et
al. (2005), individuals experiencing premorbid schizophrenia may use cannabis to alleviate
symptoms. Although cannabis has been reported to exacerbate schizophrenia symptoms, some
patients have said that they use it to "self-medicate" negative symptoms of schizophrenia,
including depression, boredom, feelings of social inadequacy, as well as to address medication
side-effects and fulfill a desire to experience positive affect and relaxation (Goswami et al.,
2004). Of note, this evidence of cannabis use as self-medication derives from anecdotal selfreports, which may be subject to denial, rationalization, and other cognitive distortions
characteristic of substance use disorder (Hall & Degenhardt, 2008). Also, many cannabis users
in the premorbid phase of schizophrenia are polydrug users (Peters et al., 2010), and the
ameliorating effects may not be attributable to cannabis solely. Epidemiological studies on
cannabis use in the premorbid phase-contrast significantly with self-reports. Self-reports
include cannabis use to reduce anxiety and "chill out." Thus, epidemiological studies on
contrasting self-reports versus psychotic features may be necessary for further research to
differentiate the immediate benefits of cannabis versus subsequent deleterious effects.
Earlier age of onset of cannabis use has also been positively correlated with more
significant cognitive deficits in schizophrenia even with a short duration of use (Solowij et al.,
2011). In a study assessing the consequences of early-onset cannabis use on learning and
memory, Solowij et al. (2002), discovered that adolescents exposed to cannabis for 2.4 years
on average displayed complex deficits in various cognitive domains than cross-referenced
groups the nonsubstance-using control group of adolescents. The findings show that the extent
and severity of cognitive deficits among adolescent cannabis users are comparable to that of
adult users (Solowij et al., 2002). However, these effects materialized after fewer than three
years of cannabis use throughout adolescence. Other research demonstrates that the earlier
the age of onset of cannabis use, the higher the association with compromised functioning,
even when magnitude and occurrence of use are controlled (Gruber et al., 2014). This
evidence suggests that early onset of use may have a deleterious effect on cognitive ability
irrespective of the magnitude of exposure (Solowij et al., 2011).
The adult literature has discussed factors that confound the association of cannabis use
with cognitive deficits and schizophrenia. These include preexisting susceptibility to
schizophrenia, frequency of use, and age of schizophrenia onset—all of which are also
important to consider for adolescents. For example, in a longitudinal study by Caspi et al.
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(2005), discovered that an existing diathesis influenced the impact of cannabis exposure on
mental illness. Only those with a concomitant, recessive variation of catechol-Omethyltransferase (COMT) showed an increased risk of schizophrenia (Caspi et al., 2005).
Environmental confounding factors include childhood trauma and growing up in a rural
neighborhood (Houston et al., 2008; Harley et al., 2010; Kuepper et al., 2011). Indeed, a recent
study examined the associations between child abuse, COMT genotypes, and psychosis, and
variability in the COMT gene only affected psychosis in individuals who reported abuse during
childhood (Alemany et al., 2014).
Evidence also indicated that cannabis exposure may contribute adversely to
neurodevelopment (Sundram, 2006). Structural imaging findings, for instance, have
demonstrated aberrations among adolescent users (Jacobus & Tapert, 2014). These effects
are consistent with previous results that indicate smaller brain and cortical gray matter volumes,
decreased prefrontal and insular cortical thickness, smaller right medial OFC volumes, smaller
hippocampal volumes, greater left than right hippocampal symmetry, larger right amygdala
volume in females, and larger amygdala in males (Wilson et al., 2000; Lopez-Larson et al.,
2011; Churchwell et al., 2010; Ashtari et al., 2011; McQueeny et al., 2011). In addition, the
finding that heavy and frequent cannabis use is positively correlated with a more prominent
aberration in prefrontal regions of the brain suggests that this region of the brain may be
particularly susceptible to the effects of cannabis use. Conversely, a smaller hippocampal mass
has been positively correlated with heavier cannabis use—a finding does not differ based on the
age of onset. This finding indicates that the duration and intensity of exposure rather than the
period at the onset of cannabis use may be more aptly associated with schizophrenia
(Lorenzetti et al., 2016). From this perspective, the decreased prefrontal volumes among heavy
and frequent users could be attributed to variables that predate their cannabis use—that is, a
preexisting diathesis (Cheetham et al., 2012). However, the study found no decrease in
hippocampal volumes among adolescents who used cannabis. This finding is consistent with
others showing that organizational differences in these brain regions are likely associated with
frequent, heavy cannabis exposure (Squeglia et al., 2009).
During the critical period of adolescence, the brain is particularly susceptible to
psychopharmacological insults. One study showed aberrations in the white matter among the
heaviest users; however, the validity of the findings may have been compromised by
confounding factors involving other substances (Baker et al., 2013). Yucel et al. (2010),
discovered among a group of 11 adolescent cannabis users, 11 adolescent inhalant users, and
8 adolescent controls, there was a significant reduction in fractional anisotropy in the fasciculus
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region adjacent to the right hippocampal area in cannabis exposed adolescents compared to
controls. In a similar study by Ashtari et al. (2009), researchers recruited 14 young males with a
history of cannabis and alcohol use who were residents of a substance abuse treatment facility.
This study presented evidence of a reduction in fractional anisotropy in addition to increased
radial diffusivity and increased trace values in frontotemporal regions in comparison to controls
(Ashtari et al., 2009). Ashtari et al. (2009), suggested that these findings point to a disruption in
the myelination process, but they also identify alcohol abuse as a confounding variable that was
not controlled. Thus, these findings could indicate a synergistic effect of both cannabis and
alcohol. Also, contemporary research has suggested an aberration in the white matter of the
brains of adolescents who partake in cannabis use while abusing alcohol simultaneously and
among adolescents without concomitant alcohol use (Jacobus et al., 2009; Bava et al., 2013;
Jacobus et al., 2013). Polydrug use can have latent effects when coupled with Cannabis sativa.
Latent Effects of Cannabis Use
Chronic use of cannabis has been consistently shown to impair numerous cognitive
processes in both adolescents and adults, such as working memory, attention, learning, and
executive functions (Ranganathan & D'souza, 2006; Solowij & Pesa, 2012). Some of the most
salient consequences have been found in information coding, verbal and nonverbal
communication retrieval, and consolidation (Wilson et al., 1994; D'Souza et al., 2004; Ilan et al.,
2004; Lane et al., 2005). In these studies, impairment has also been consistently noted in
focused, selective, and divided attention. Most significantly, cannabis exposure during
adolescence has been shown to produce schizophrenia-like cognitive impairments in otherwise
healthy individuals (D'Souza et al., 2004; Morrison et al., 2009). However, it is essential to clarify
that a systematic review of studies examining the effects of acute administration of THC yielded
variable results across a wide range of domains (Zuurman et al., 2009). Researchers
determined that while memory and attention effects showed many dose-response associations,
results were not reproducible with differing neurocognitive tests. Furthermore, only heart rate
served as a measurable and consistent biomarker of cannabis intoxication (Lubman et al.,
2015).
Former users who commenced use during adolescence demonstrate lower cerebral
blood flow in prefrontal, orbitofrontal cortices, cerebellum, striatum, temporal lobes, and globally
(Lundqvist et al., 2001; Sevy et al., 2008). Also, in the study, a positive correlation of
schizophrenia-like symptoms and cannabis exposure was observed in former users who began
use during adolescence with no history of schizophrenia or a schizophreniform disorder
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(Lundqvist et al., 2001). This study included participants who began cannabis use in
adolescence but abstained during adulthood. This evidence suggests that a diathesis may not
require psychotic symptoms amongst heavy cannabis users (Yücel et al., 2008). Although this
evidence still does not establish a causal relationship between heavy cannabis use and
psychosis, it suggests that a correlational relationship should not be discounted.
Although evidence of structural aberrations related to cannabis use is not enough to
provide evidence of a causal association between cannabis use and psychosis or
schizophrenia, this evidence exists among adolescents and adults who have used cannabis
(Lorenzetti et al., 2016). Although findings for brain regions were varied, evidence supports
those reductions in parahippocampal and hippocampal volumes were associated with greater
lifetime cannabis exposure (Yücel et al., 2008). In a recent study, hippocampal shape
alterations were examined in cannabis users with and without schizophrenia. Researchers
found that aberrations in morphology across the hippocampus were associated with heavy
cannabis use and symptoms of psychosis (Solowij et al., 2013). These findings point towards a
positive correlation between greater cannabis use and morphological alterations in
parahippocampal and hippocampal regions; however, as stated previously, the paucity of this
research and varied findings in current studies warrant further investigation to clarify the
association between cannabis use and parahippocampal and hippocampal aberrations in users.
In addition to Magnetic Resonance Imaging (MRI) studies, researchers have used
Diffusion Tensor Imaging (DTI) to evaluate white matter in adult cannabis users. This process
involves mapping water molecule diffusion, white matter microstructure, and anatomical
connectivity. Due to other substances besides cannabis, it has been challenging to isolate
THC; thus, these studies have been limited. However, the few studies that have been
conducted support the notion that heavy cannabis use is associated with abnormalities in the
white matter within the frontal, brain regions, hippocampal regions, and the corpus callosum
(Gruber & Yurgelun-Todd, 2005; Gruber et al., 2012). In addition, many of these studies have
also supported the notion that poor white matter integrity positively correlates with early-onset
cannabis use (Gruber et al., 2012; Zalesky et al., 2012; Gruber et al., 2014). For example,
Zalesky et al. (2012), reported anomalies in axonal fiber connectivity in the right fimbria of the
hippocampus, splenium of the corpus callosum, and commissural fibers. There was also
evidence of impaired connectivity in the fimbria and commissural fibers that are positively
correlated with the age of onset of heavy cannabis use (Zalesky et al., 2012)—a finding that
persisted after controlling for duration of consistent use and that supports the notion that heavy
cannabis use during adolescence may be more harmful than adult exposure. Furthermore, it
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supports studies in adults showing that the earlier that age of onset of cannabis use, the greater
the cognitive impairment and more pronounced morphological aberrations (Jacobus et al., 2009;
Lorenzetti et al., 2020). This comparison of heavy cannabis use effects in adults and
adolescents extends to the Intelligence Quotient (IQ).
Meier et al. (2012), conducted a longitudinal study utilizing the Wechsler Intelligence
Scale for Children-Revised, or Adults-IV administered to seven, nine, eleven, thirteen, and
eighteen-year-olds. Those tested determined to be dependent on cannabis before the age of
eighteen had a 0.55 standard deviation reduction in IQ compared to those defined as dependent
after eighteen years of age (Meier et al., 2012). In addition, adolescents, seemingly, are more
vulnerable to intellectual deficits succeeding cannabis use than adults (Gorey et al., 2019).
Conclusion
In this literature review, the impact of cannabis use on the adolescent brain and the
associations of cannabis use with psychosis and schizophrenia during adolescence were
considered. Indeed, many harmful effects of frequent cannabis use seem to predicate whether
cannabis use commences during adolescence. However, it is critical to consider the inimitable
neurobiological aberrations and potential confounds occurring during this crucial period. The
outcomes of cannabis use on the endocannabinoid system have been contextualized regarding
neuromaturation occurring throughout adolescence. A summary of the literature on the effects
of cannabis use among those with and without a predisposition to schizophrenia has also been
presented. The influence of cannabis use was considered on the developing endocannabinoid
system, explicitly highlighting the results of studies examining if heavy and frequent cannabis
exposure is positively correlated with significant morphological aberrations in white matter
neuromaturation development. This review will contribute to the literature and understanding of
the susceptibility of this population and elucidate the contradictions and ambiguities in the
research on cannabis exposure and developmental psychiatry and psychology. Implications for
further research include the likely instances of polydrug use. In many situations, cannabis users
abuse psychedelics, alcohol, and narcotics in conjunction with cannabis. Polydrug use may
cause various mental health pathologies and warrants further investigation.
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